L. Kessler

ORCID: 0000-0002-1769-5625
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic function and diabetes
  • Diabetes Management and Research
  • Diabetes Treatment and Management
  • Diabetes and associated disorders
  • Renal Transplantation Outcomes and Treatments
  • Cystic Fibrosis Research Advances
  • Transplantation: Methods and Outcomes
  • Cannabis and Cannabinoid Research
  • Obstructive Sleep Apnea Research
  • Metabolism, Diabetes, and Cancer
  • Neuroscience of respiration and sleep
  • Diabetic Foot Ulcer Assessment and Management
  • Pancreatitis Pathology and Treatment
  • Organ Transplantation Techniques and Outcomes
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Extracellular vesicles in disease
  • Genetics and Neurodevelopmental Disorders
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Neuroendocrine Tumor Research Advances
  • Diabetes Management and Education
  • Pancreatic and Hepatic Oncology Research
  • Pituitary Gland Disorders and Treatments
  • Neonatal Respiratory Health Research
  • Birth, Development, and Health
  • Chronic Obstructive Pulmonary Disease (COPD) Research

Regenerative NanoMedicine
2016-2025

Inserm
2001-2025

Université de Strasbourg
2016-2025

Hôpitaux Universitaires de Strasbourg
2015-2025

EM Strasbourg Business School
2022

Hôpital Civil, Strasbourg
2009-2019

Centre Hospitalier Universitaire Amiens-Picardie
2016

Mitochondrie, stress oxydant et protection musculaire
2015

Hôpital d'Hautepierre
2001-2015

Institut du Thorax
2014

To study the effect of systemic hyperbaric oxygenation (HBO) therapy on healing course nonischemic chronic diabetic foot ulcers.From 1999 to 2000, 28 patients (average age 60.2 +/- 9.7 years, diabetes duration 18.2 6.6 years), whom 87% had type 2 diabetes, demonstrating Wagner grades I-III ulcers without clinical symptoms arteriopathy, were studied. They randomized undergo HBO because their did not improve over 3 months full standard treatment. All demonstrated signs neuropathy. was applied...

10.2337/diacare.26.8.2378 article EN Diabetes Care 2003-08-01

OBJECTIVE To describe the 5-year outcomes of islet transplantation within Swiss-French GRAGIL Network. RESEARCH DESIGN AND METHODS Retrospective analysis all subjects enrolled in GRAGIL-1c and GRAGIL-2 trials. Parameters related to metabolic control, graft function, safety were studied. RESULTS Forty-four patients received (islet alone [ITA] 24 [54.5%], after kidney [IAK] 20 [45.5%]) between September 2003 April 2010. Recipients a total mass 9,715.75 ± 3,444.40 IEQ/kg. Thirty-four completed...

10.2337/dc15-0094 article EN Diabetes Care 2015-06-11

High glucose (HG)-induced endothelial senescence and dysfunction contribute to the increased cardiovascular risk in diabetes. Empagliflozin, a selective sodium co-transporter2 (SGLT2) inhibitor, reduced of mortality type 2 diabetic patients but protective mechanism remains unclear. This study examines role SGLT2 HG-induced dysfunction. Porcine coronary artery cultured cells (ECs) or segments were exposed HG (25 mmol/L) before determination senescence-associated beta-galactosidase activity,...

10.1111/jcmm.14233 article EN cc-by Journal of Cellular and Molecular Medicine 2019-03-30

Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to genetic variants in Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators, first therapy available, have transformed management CF. The latest standards care from European CF Society (2018) did not include guidance on as modulators were becoming established a novel therapy. We produced interim guide healthcare professionals provision for people with Here we provide evidence-based covering...

10.1016/j.jcf.2022.10.002 article EN cc-by Journal of Cystic Fibrosis 2022-10-28

Aim: To evaluate the evolution of glycemic outcomes in patients living with type 1 diabetes (T1D) after year use MiniMed 780G advanced hybrid closed-loop (AHCL) system. Methods: We conducted an observational, retrospective, multicentric study 20 centers France. The primary objective was to improvement control 1-year AHCL. endpoint variation time range (TIR) between pre-AHCL and Secondary objectives were analyze 3, 6, 12 months AHCL use, safety, long-term observance Results: Two hundred...

10.1089/dia.2023.0414 article EN Diabetes Technology & Therapeutics 2024-01-18

Background. New-onset diabetes after transplantation (NODAT) increases infectious and cardiovascular complications reduces patient graft survival. We assessed the incidence risk factors for glucose metabolism abnormalities before kidney using an oral tolerance test (OGTT). The purpose of study was to better identify patients at NODAT adapt their immunosuppressive treatment management transplantation. Methods. OGTT performed in 243 placed on waiting list between January 1, 2005, December 31,...

10.1097/tp.0b013e31820f0877 article EN Transplantation 2011-02-18

Abstract Aims Few reports have assessed the relationship between Type 1 diabetes and sleep disorders. The purposes of our study were to determine prevalence obstructive apnoea in compare clinical profile people with or without apnoea. Methods In this cross sectional 67 consecutive diabetes, we performed polysomnography as part their yearly check‐ups. Results cohort, a mean BMI 25.8 ± 4.7 kg/m 2 , [apnoea–hypopnoea index ( AHI ) > 10/h] was 46%. Severe ≥ 30/h) present 19% patients. We...

10.1111/dme.12582 article EN Diabetic Medicine 2014-09-03

Abstract Aim To study prospectively two methods for the bacteriological diagnosis of osteomyelitis related to diabetic foot ulcer: needle puncture performed across normal skin surrounding ulcer and superficial swabbing ulcer. Patients Diabetic patients with a complicated by bone or joint infection, as detected X‐ray imaging, were included in study. Ulcer each patient. reach tissue nearest surface, was guided imaging drop fluid obtained aspiration used both aerobic anaerobic bacterial...

10.1111/j.1464-5491.2005.01764.x article EN Diabetic Medicine 2005-11-24

Aim: Continuous intraperitoneal insulin infusion (CIPII) with the DiaPort system using regular was compared to continuous subcutaneous (CSII) Lispro, investigate frequency of hypoglycemia, blood glucose control, quality life, and safety. Methods: In this open, randomized, controlled, cross‐over, multinational, 12‐month study, 60 type 1 diabetic patients frequent hypoglycemia and/or HbA1c > 7.0% CSII were randomized CIPII or CSII. The aim obtain best possible while avoiding hypoglycemia....

10.1111/j.1463-1326.2009.01059.x article EN Diabetes Obesity and Metabolism 2009-09-09

Background. Whether islet transplantation should be aimed at restoring insulin independence or providing adequate metabolic control is still debated. The GRAGIL2 trial was designed as a phase 1–2 study where primary outcome the rate of independence, and secondary success defined by composite score based upon basal C-peptide, HbA1c, hypoglycemic events, exogenous needs. Methods. C-peptide negative type 1 brittle diabetic patients experiencing severe hypoglycemia were eligible to receive...

10.1097/01.tp.0000268511.64428.d8 article EN Transplantation 2007-07-09

To describe the 10-year outcomes of islet transplantation within Swiss-French GRAGIL Network, in patients with type 1 diabetes experiencing high glucose variability associated severe hypoglycemia and/or functional kidney graft. We conducted a retrospective analysis all subjects transplanted GRAGIL-1c and GARGIL-2 trials analyzed components metabolic control, graft function safety over period follow-up. Forty-four were included between September 2003 April 2010. Thirty-one completed Ten years...

10.1111/ajt.16637 article EN cc-by-nc-nd American Journal of Transplantation 2021-05-09

Background: Evaluate the impact of MiniMed™ 780G advanced hybrid closed-loop (AHCL) system on glucose profile pregnant women with type 1 diabetes (T1D) and maternal-neonatal complications. Methods: From April 2021 to September 2022, T1D treated AHCL were included in an observational multicenter retrospective study. Continuous monitoring parameters analyzed monthly during pregnancy as well Results: Thirteen women, including a twin (age: 33 ± 3 years, hemoglobin A1c [HbA1c]: 7.3% 0.7%, insulin...

10.1089/dia.2023.0267 article EN Diabetes Technology & Therapeutics 2023-11-13

After pancreatic islet transplantation, insufficient blood supply is responsible for the loss of viability. The aim our study was: 1) to determine influence vascular endothelial growth factor (VEGF) on survival encapsulated rat islets transplanted into healthy and diabetic mice 2) evaluate metabolic efficiency VEGF-supplemented grafts. Twenty-four hours after culture, 50 immobilized collagen in presence VEGF (100 ng/ml) (AN69 membrane, HOSPAL) were grafted peritoneal cavity or...

10.3727/000000003108747109 article EN Cell Transplantation 2003-09-01

Background. Since the Edmonton trial in 2000, increasing numbers of transplant centers have been implementing islet transplantation programs. Some institutions elected to associate multicenter networks, such as Swiss-French GRAGIL (Groupe Rhin-Rhône-Alpes-Genève pour la Transplantation d'Îlots de Langerhans) consortium. Methods. All pancreata offers University Geneva Cell Isolation and Center from within network 2002 2003 were reviewed. Islet preparations attributed most suitable recipient...

10.1097/01.tp.0000161224.67535.41 article EN Transplantation 2005-05-01

Rigorous assessment of health-related quality life (HRQL) is mandatory to establish the benefits islet transplantation.The 36-Item Short Form Health Survey (SF-36) and Diabetes Quality Life (DQOL) scales were completed by patients included in an Islet Transplantation Alone (ITA) trial (n = 10) After Kidney (IAK) 10).The two populations differed HRQL scores at baseline, with poorer ITA patients. SF-36 for physical limitations, bodily pain, general health perception, social functioning,...

10.1111/j.1464-5491.2009.02731.x article EN Diabetic Medicine 2009-04-17

Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort 49 patients who were successfully grafted with allogenic islets and determined that appearance donor-specific anti-HLA antibodies (DSAs) did not accelerate rate islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound allogeneic targets expressed by cells induced their destruction in vitro; however, passive transfer same affect survival murine models. Live...

10.1172/jci93542 article EN Journal of Clinical Investigation 2017-11-19
Coming Soon ...